Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Alfredo Zurlo"'
Autor:
Alfredo Zurlo, Beate Habel, Hans Baumeister, Maxim Kebenko, Elena Garralda, M. Macchini, I. Ahrens-fath, Konrad Klinghammer, G. Del Conte, Walter Fiedler, Christina C Rolling, S. Ochsenreiter
Publikováno v:
European Journal of Cancer. 138:S5-S6
Autor:
Sebastian Ochsenreither, Alfredo Zurlo, Elena Garralda, Ignacio Matos, Konrad Friedrich Klinghammer, Gianluca Del Conte, Marina Macchini, Christina C Rolling, Maxim Kebenko, Omar Saavedra Santa Gadea, Francesco Raspagliesi, Domenica Larusso, Isabelle ahrens-Fath, Beate Habel, Hans Baumeister, Walter M. Fiedler
Publikováno v:
Journal of Clinical Oncology. 39:2524-2524
2524 Background: The phase I GATTO study explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab (GAT), a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin-1 (TA-MUC1) and an anti-
Autor:
Hans Baumeister, Elena Garralda, Francesco Raspagliesi, Isabelle ahrens-Fath, M. Macchini, Konrad Klinghammer, Maxim Kebenko, Ignacio Matos, Alfredo Zurlo, Omar Saavedra Santa Gadea, Christina C Rolling, Sebastian Ochsenreither, Beate Habel, Walter Fiedler, Domenica Larusso, Gianluca Del Conte
Publikováno v:
Journal of Clinical Oncology. 39:2522-2522
2522 Background: The phase I GATTO study explored the feasibility, tolerability and preliminary activity of combining Gatipotuzumab (GAT), a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin-1 (TA-MUC1), and an anti
Autor:
Hans Baumeister, Christina Dicke, Elena Garralda, Ignacio Matos, Domenica Lorusso, Alfredo Zurlo, Ulrich Keilholz, L. Gianni, J. Tabernero, G. Del Conte, M.E.H.M. Van Hoef, Walter Fiedler, Konrad Klinghammer, Beate Habel, Sebastian Ochsenreither, Francesco Raspagliesi, Maxim Kebenko
Publikováno v:
Annals of Oncology. 29:viii547
Autor:
Domenica Lorusso, Elena Garralda, Ignacio Matos, Ulrich Keilholz, Alfredo Zurlo, Josep Tabernero, Riccardo Belli, Hans Baumeister, Maxim Kebenko, Gianluca Del Conte, Luca Gianni, Konrad Klinghammer, Christina Dicke, Francesco Raspagliesi, Beate Habel, Walter Fiedler, Sebastian Ochsenreither
Publikováno v:
Journal of Clinical Oncology. 36:TPS2596-TPS2596
TPS2596Background: TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a competitive antagonist at the ligand binding site. GAT (PankoMab-GEX) is a no...
Autor:
Bozena Kukielka-Budny, Alina Turcu, Philippe Debourdeau, Sylvie Rottey, Alfredo Zurlo, Cristina-Marinela Oprean, Andrzej Kawecki, Ulrich Keilholz, B. Zurawski, Javier Lavernia, Anca C. Mihailov, Bruno Dietrich, Jérôme Fayette, Ilaria Imarisio, Andreas Dietz, Simona Mihutiu, Gunnar Folprecht, Michael Schenker, Philippe Schafhausen, Sebastian Ochenduszko
Publikováno v:
Journal of Clinical Oncology. 36:59-59
59 Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU (F), and the epidermal growth factor receptor (EGFR) blocking monoclonal antibody cetuximab. CetuGEX is a new monoclonal antibody sharing the identical EGFR-bindin
Publikováno v:
Journal of Clinical Oncology. 36:61-61
61 Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU (F), and the EGFR blocking monoclonal antibody (mAb) cetuximab (C). The mAb CetuGEX (CG) shares with cetuximab the identical EGFR-binding domain, but harbors a def
Autor:
Antje Danielczyk, Jens Weidmann, Steffen Goletz, Marc Salzberg, Henning Schulze-Bergkamen, Cristiana Sessa, Alfredo Zurlo, Hans Baumeister, Walter Fiedler, Sara Cresta, Bruno Dietrich, Sara De Dosso, Luca Gianni, Anna Tessari
Publikováno v:
ESMO Open
Background Changes in glycosylation of the constant domain (Fc) of monoclonal antibodies (mAbs) enhance antibody-dependent cell-mediated cytotoxicity independently of downstream effects following receptor blockade by the antibody, thus extending thei
Autor:
Anselmo Ap, Franco Mandelli, Mattia Falchetto Osti, V Iacari, Riccardo Maurizi Enrici, Alfredo Zurlo
Publikováno v:
European Journal of Haematology. 63:126-133
Between January 1972 and December 1982 60 patients with pathological stage IA and IIA Hodgkin's disease (HD) were submitted to Mantle irradiation only. Twenty-five were in stage I (32.1%) and 35 in stage II (67.9%). All patients were submitted to sta
Publikováno v:
Oncology. 75:215-223
Background: Köhne et al. [Ann Oncol 2002;13:308–317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with diff